Analysis
Startups are still acquiring other startups at a fast clip in 2026, with the buying concentrated among a small group of ultra-high-valuation unicorns, according to Crunchbase News data. OpenAI is the single most prolific buyer, having acquired 8 startups so far in 2026 alone -- 19 total historically -- primarily seed- and early-stage companies in AI. Anthropic has completed at least 5 acquisitions this year, including the $400 million purchase of AI biotech startup Coefficient Bio. MoonPay closed 5 separate cryptocurrency and blockchain acquisitions between April and July.
The pattern extends the logic Pulse has tracked across OpenAI's agent-everything push this week: well-capitalized platforms are treating acquisition as a faster substitute for internal build cycles, buying teams and technology rather than developing capability from scratch, especially in categories moving too fast for a multi-quarter internal roadmap to keep pace. Databricks, Cyera, Harvey and Legora round out the list of active acquirers named in the data, spanning AI infrastructure, security and legal tech.
“Databricks, Cyera, Harvey and Legora round out the list of active acquirers named in the data, spanning AI infrastructure, security and legal tech.”
- OpenAI -- 8 acquisitions in 2026, 19 total, overwhelmingly seed- and early-stage AI teams
- Anthropic -- 5-plus 2026 deals including the $400M Coefficient Bio purchase, extending into AI biotech
- MoonPay -- 5 crypto/blockchain acquisitions between April and July, showing the pattern outside AI labs
The scale of the underlying market is notable: more than 440 funded startups sold to other startups in the first half of 2026, a volume that has rebounded sharply from the post-2022 funding slowdown, driven specifically by AI investment. That volume has since cooled -- fewer than 100 such deals have closed in the second half of the year so far, which could reflect either a genuinely thinner pool of attractive acquisition targets remaining, or acquirers becoming more selective as valuations for the best remaining teams climbed.
For founders, the through-line is that 'sell to a bigger unicorn' has become a real and increasingly normalized exit path distinct from both an IPO and a traditional strategic acquisition by a public company -- speed and talent access are the currency in these deals more than product-market fit or revenue, which changes what an early-stage team should optimize for if this is the exit they're building toward.
